NorthWest Biotherapeutics Inc (NWBO)

[no2koolaid]

This is absolutely spot on...

it's actually much easier in the UK with a single primary payor

Even with EMA approval, the individual governments in the EU are the independent buyers. As a result, market access involves establishing approved pricing and is key to the success of any drug in Europe. It must be realized on a country-by-country basis, unlike in the United States where there are many payers; though that creates another set of issues not the least of which is the conundrum created by PBMs.

For the most part, in Europe, each country is a single payer, government-run health care system. In most countries of Europe, a drug cannot be launched successfully until a price is proposed, negotiated and agreed upon...country by country!